Rev Esp Quimioter 2024, April 9
Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain
LUCÍA FRAILE GARCÍA, JESÚS ARAMBURU ARNUELOS, ÉRIC LÓPEZ GONZÁLEZ, ALBA BELLÉS-BELLÉS, ALBA MUÑOZ SANTA, ELENA SÁNCHEZ BÁSCONES, SARAY MORMENEO BAYO, ALBERT BERNET SÁNCHEZ, IVÁN PRATS SÁNCHEZ, ALEJANDRO CUMPLIDO PORTILLO, MERCÈ GARCÍA GONZÁLEZ
Published: 9 April 2024
http://www.doi.org/10.37201/req/015.2024
Introduction. Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area.
Material and methods. A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG & AziR Assay and AllplexTM MG & MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene.
Results. A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%).
Conclusions. The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.
Rev Esp Quimioter 2024; April 9 [Full-text PDF]
